We remain committed to implementing changes to introduce biosimilar medicines where they would release additional funds for PHARMAC to invest in other medicines for the benefit of New Zealanders.In February 2019, the Pharmacology and Therapeutics Advisory Committee (PTAC) reviewed a funding application for a biosimilar rituximab and recommended that PHARMAC run a competitive process for the supply of rituximab for currently funded indications. All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Approvals valid for 6 months for applications meeting the following criteria.2.1 Treatment with at least 3 immunosuppressants (oral and intravenous steroids, cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or2.2 Rapid treatment is required due to life threatening complications; andRenewal – (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or any other medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria.Initial application – (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or any other medical practitioner on the recommendation of a neurologist. Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office.Rituxan Genetech BioOncology Co-pay Card: Eligible patients may pay $5 copay per prescription and receive an annual savings of up to $25,000 per year; for additional information contact the program at 855-692-6729.Rituxan Hycela Genetech BioOncology Co-pay Card: Eligible patients may pay $5 copay per prescription and receive an annual savings of up to $25,000 per year; for additional information contact the program at 855-692-6729.Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines to low income or uninsured and under-insured people who meet specific guidelines. Rituximab would be given by intravenous infusion once every two months for two years after … Very common (10% or more): Hypotension (10%) Common (1% to 10%): Hypertension, orthostatic hypotension, myocardial infarction, arrhythmia, atrial fibrillation, tachycardia. We propose to widen funded access to rituximab for a range of uses. Approvals valid for 12 months for applications meeting the following criteria:Initial application – (graft versus host disease) from any relevant practitioner. The “Inj 1 mg for ECP” formulation of rituximab listed in Section B of the Schedule allows DHBs to claim a subsidy for the correct number of mg provided by the compounder.We are aware of extended stability data that supports a prolonged shelf life of rituximab infusions prepared with Mabthera. Rituxan Prices. Rituxan (rituximab) is a member of the antirheumatics drug class and is commonly used for Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and others.The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.Please note: This is a drug discount program, not an insurance plan. For some indications it is only used for a fixed amount of time. See below for summary of clinical advice for biosimilar rituximab. *Unapproved indication. If this proposal is approved, PHARMAC intends to seek further clinical advice from the relevant Subcommittees to determine if there are other changes to rituximab criteria that could be considered at a later date. There would be some impact on DHB infusion services if access to rituximab is widened to include maintenance treatment for patients with non-Hodgkin’s lymphoma. Feedback from this consultation will help us decide if this agreement should be confirmed.We understand there is interest in funding for other uses of rituximab. Available for Android and iOS devices. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements.